Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and ...

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.2% at $449.52. This change lagged the S&P 500's 1.16% loss on the day. Meanwhile, the Dow experienced a drop of 0.47%, and the ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

With a volume of 1,752,912, the price of VRTX is up 1.48% at $439.58. RSI indicators hint that the underlying stock may be overbought. Next earnings are expected to be released in 68 days.

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, May 5, 2025. For those trading based on events, analyzing historical stock behavior around earnings announcements can be ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

We have seen 790 institutional investors add shares of $VRTX stock to their portfolio, and 790 decrease their positions in their most recent quarter. $VRTX insiders ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.